Return to program book search

Session Information

SYM S048 - Cutaneous Lymphomas

Open admission to eligible categories, no tuition or ticket

Subject:

Date: Monday, March 04

CME Credits: 3.00

Location: Room B121/122

Time: 2:00 PM - 5:00 PM

Director: Ellen J. Kim, MD, FAAD

Speakers:

  • Madeleine Duvic, MD, FAAD
  • Joan Guitart, MD, FAAD - Handout
  • Youn H. Kim, MD, FAAD
  • Alain H. Rook, MD, FAAD
  • Gary S. Wood, MD, FAAD - Handout

Learning Objectives:
Following this course, the attendee should be able to:

  • Identify advances in MF/SS pathogenesis and diagnosis
  • Order appropriate diagnostic and staging tests
  • Differentiate treatments for low vs. high risk patients, pediatric vs. adult patients.

Description:
The field of mycosis fungoides/Sezary Syndrome (MF/SS) has undergone many recent advances. This session will focus on MF/SS basic science and immunology updates, diagnostic challenges, pediatric MF, and management of early vs. advanced patients.

References:

  • Survival outcomes and prognostic factors in mycosis fungoides/S├ęzary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European .Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 2010 Nov 1;28(31):4730-9.
  • Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Br J Haematol 2011 Oct;155(2):150-66.
  • Long-term Outcomes of 1,263 Patients with Mycosis Fungoides and Sezary Syndrome from 1982 to 2009. Clin Cancer Res 2012 Aug 23.

Schedule:

Monday, March 04
2:00 PMIntroduction / Dr. Kim
2:05 PMMF/SS pathophysiology and histologic/molecular tools / Dr. Wood
2:35 PMNot yet CTCL: cutaneous T-cell dyscrasias and mimics / Dr. Guitart
3:05 PMMF management: pediatric MF and other updates / Dr. Kim
3:35 PMSezary Syndrome immunobiology and therapies / Dr. Rook
4:05 PMAdvanced MF/SS: new frontiers / Dr. Duvic
4:35 PMCase discussion and Questions / Dr. Kim